试验注册
评估 [14C]-MK-4208/[14C]-TERN-701 在健康成年男性中的临床试验 (MK-4208-002/TERN701-1016)
A Clinical Trial to Evaluate [14C]-MK-4208/[14C]-TERN-701 in Healthy Adult Male Participants (MK-4208-002/TERN701-1016)
作者：Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
ClinicalTrials.gov · 2026年9月24日 · Terns, Inc., a subsidiary of Merck & Co…
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要）…
已等待 0 秒大约需要 10–20 秒
可以先看别的，做好了会自动出现在这里。
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要一两分钟。
摘要Abstract
Brief summary: The goal of the study is to learn what happens to different forms of TERN-701 medications in a healthy person's body over time. Researchers will compare what happens to different forms of TERN-701 in a person's body over time. The goal of the study is to learn: * What happens to different forms of TERN-701 in a person's body over time. * The amount and number of different forms of TERN-701 that leave a person's body over time.
Conditions: Healthy
Interventions: drug: TERN-701 (MK-4208, HS-10382)
Phase: Phase 1
Enrollment: 8 (actual)
Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (industry)
Countries: United States
Status: completed
还没有查过关联研究
我会去找这篇研究之前的基础工作、做类似事情的研究，以及之后引用它的研究，并说明每篇为什么相关。